ClinicalTrials.gg
CompletedNCT07016516Updated Dec 4, 2025

A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects

A Phase 1 interventional study of PRT-064040 nasal spray and Placebo in Migraine, sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.

Enrollment
50th of 61
80 · median 288
Started
2025
with 12 others
Phase 1
3 of 80
none open now
Registered
65th of 80
by date

Among the 80 studies in Migraine Disorders with a site in China, this one is the 50th largest by enrollment of the 61 interventional ones that give a count, is one of 13 that started in 2025, is one of 3 in phase 1, and was the 65th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in China, or all of them as a file.
02

Study summary

This trial is a Phase I, single-center, randomized, double-blind, placebo-controlled study conducted in healthy Chinese adult subjects.

The purpose of this study is to learn about:

  • Safety and tolerability of PRT-064040 nasal spray in healthy adult subjects.
  • Pharmacokinetics after single and multiple dose of PRT-064040 nasal spray in healthy Chinese adult subjects.

This study is divided into two parts:

  • Eligible subjects in Part A will receive a single dose of PRT-064040 nasal spray or placebo.
  • Eligible subjects in Part B will receive multiple doses of PRT-064040 nasal spray or placebo, administered once daily (QD) for a total of 7 consecutive days.
03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female Chinese adults aged ≥18 years and ≤55 years.
  2. of 18 to 28 kg/m\^2; and a total body weight ≥50 kg for males and ≥45 kg for females.

Exclusion criteria

Exclusion Criteria:

  1. History of allergy to any medications, foods, or other substances.
  2. History or presence of any severe diseases that are considered by the investigator.
  3. Any clinically significant abnormal laboratory test results or positive test.
  4. Any nasal conditions or diseases that, in the investigator's judgment, may significantly affect the administration or absorption of a nasal product.
  5. Standard 12-Lead that demonstrates clinically relevant abnormalities.
  6. Pregnant or breastfeeding women, or those with a positive pregnancy test result during screening.
  7. Positive urine drug screen, alcohol breath test, or nicotine test.
  8. History of significant alcohol abuse or drug abuse.
  9. Donation or loss of blood of approximately 400 mL or more within 3 months prior to dosing.
  10. Previous participation in another clinical trial and receiving the drug within 3 months prior to dosing.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Single dose of PRT-064040 nasal spray

    Drug: PRT-064040 nasal spray

  • Placebo comparator
    Single dose of Placebo

    Drug: Placebo

  • Experimental
    Multiple doses of PRT-064040 nasal spray

    Drug: PRT-064040 nasal spray

  • Placebo comparator
    Multiple doses of Placebo

    Drug: Placebo

Interventions

  • DrugPRT-064040 nasal spray

    A single dose of PRT-064040 nasal spray at one of six dose levels

  • DrugPlacebo

    A single dose of Placebo at one of six dose levels

  • DrugPRT-064040 nasal spray

    Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days

  • DrugPlacebo

    Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: From first dose to maximum of 2 days post last dose administration

Secondary outcomes

  1. Pharmacokinetic Parameters: Cmax

    Time frame: Up to 2 days post last dose administration

  2. Pharmacokinetic Parameters: Tmax

    Time frame: Up to 2 days post last dose administration

  3. Pharmacokinetic Parameters: AUC

    Time frame: Up to 2 days post last dose administration

  4. Pharmacokinetic Parameters: Half life

    Time frame: Up to 2 days post last dose administration

07

Study locations

1 site
  • The Third Hospital of Changsha
    Changsha, Hunan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2025, 3 months.

Of 39 industry-sponsored phase 1 interventional studies under Migraine Disorders, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 3 months is below that.

Counting every sponsor, half of 53 studies reached it within 6 months; a quarter within 2 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 11, 2025
StartActual
Jun 7, 2025
Primary completionActual
Sep 8, 2025
CompletionActual
Sep 8, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016516
Lead sponsor
Sichuan Purity Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 7, 2025
Primary completion
Sep 8, 2025
Completion
Sep 8, 2025
Last update
Dec 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion